Active Ingredient History

  • Now
Brivanib alaninate (INN/USAN) also known as BMS-582664 is an investigational, anti-tumorigenic drug for oral administration. The drug is being developed by Bristol-Myers Squibb for the treatment of hepatocellular carcinoma or HCC, the most common type of liver cancer. Brivanib is no longer in active development.   Wikipedia

  • SMILES: C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N
  • Mol. Mass: 441.46
  • ALogP: 3.42
  • ChEMBL Molecules:
More Chemistry
bms540215 | bms 540215 | bms-540215 | bms582664 | bms 582664 | bms-582664 | brivanib | brivanib alaninate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue